ReviewJACC. CardioOncology2020
COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.
Review in JACC. CardioOncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- COVID-19's immuno-pathology and cardiovascular diseases.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Review
- COVID-19 and the Heart: Could Transient Takotsubo Cardiomyopathy Be Related to the Pandemic by Incidence and Mechanisms?Frontiers in cardiovascular medicine · 2022Article
- Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis.Computers in biology and medicine · 2021Article
- Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface.Pathogens (Basel, Switzerland) · 2021Review
- A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic.Cardio-oncology (London, England) · 2021Article
- An unexplained death after routine cardiac surgery: how long have we dealt with coronavirus disease 2019?Interactive cardiovascular and thoracic surgery · 2020Article
- Reflections on Our Inaugural Year ofJACC. CardioOncology · 2020Article
- Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?Journal of the American College of Cardiology · 2020Article
- Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World.Frontiers in cardiovascular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.